Sputum cfDNA for Detection of Multiple Driver Genes Alterations in LAC
The utility of sputum cell-free DNA (cfDNA) as a surrogate material for detecting EGFR mutations...
Read MoreOct 6, 2022
The utility of sputum cell-free DNA (cfDNA) as a surrogate material for detecting EGFR mutations...
Read MoreOct 6, 2022
When non-small cell lung cancer (NSCLC) patients were first diagnosed, metastases were common. On...
Read MoreOct 6, 2022
Patients with hematologic malignancies have had encouraging outcomes using T-cell-recruiting...
Read MoreOct 5, 2022
Autoantibody production or abnormalities in the genes that code for coagulation factors may result...
Read MoreOct 5, 2022
The best course of treatment for certain patients with acute myeloid leukemia (AML) is allogeneic...
Read MoreOct 5, 2022
MONDAY, Oct. 3, 2022 (HealthDay News) — An electronic alert-triggered, patient-centered...
Read MoreOct 5, 2022
MONDAY, Oct. 3, 2022 (HealthDay News) — In a clinical report issued by the American Academy...
Read MoreOct 5, 2022
MONDAY, Oct. 3, 2022 (HealthDay News) — For early-stage invasive breast cancer, involved or...
Read MoreOct 5, 2022
MONDAY, Oct. 3, 2022 (HealthDay News) — For a sample of 60 drugs, research and development...
Read MoreOct 5, 2022
TUESDAY, Oct. 4, 2022 (HealthDay News) — Medicare eligibility and enrollment at age 65 years...
Read MoreOct 5, 2022
The heterogeneous T-cell neoplasm known as peripheral T-cell lymphomas (PTCLs) is frequently...
Read MoreOct 5, 2022
When exposed to ambient air compared to physioxia, hematopoietic stem cells (HSCs) exhibit...
Read MoreOct 5, 2022
There wasn’t enough proof to support the preventive use of tranexamic acid (TXA) in...
Read MoreOct 5, 2022
Androgen axis modulators, PARP inhibitors, and PSMA theranostics have all been demonstrated to...
Read MoreOct 5, 2022
Patients with metastatic castrate-sensitive prostate cancer (mCSPC) must deal with pain as a...
Read MoreOct 5, 2022
Researchers had previously demonstrated the potential validity of radiographic progression-free...
Read MoreOct 5, 2022
For patients with mCSPC, the current standard of treatment is to intensify androgen deprivation...
Read MoreOct 5, 2022
When added to the protocol-allowed standard of care (SoC) in patients with progressive,...
Read MoreOct 5, 2022
ADT + DOC was adopted as the norm for care in MHSPC. Clinical studies CHAARTED and STAMPEDE...
Read MoreOct 5, 2022
Patients were enrolled in PROpel regardless of the presence of HRR gene mutations (HRRm). The...
Read More